THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Lobbying for THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)

Filing 1st Quarter - Report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 20, 2026

Expenses

$3,490,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 1

JESSICA HATCHER New on this filing

Previously held: Rep. Jake Auchincloss (D-MA) - Legislative Director 1/2021-3/2023, Rep. Pramila Jayapal (D-WA) - Senior Legislative Assistant, 5/2020-12/2020; Legislative Assistant, 4/2018-4/2020

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 6

Centers For Medicare and Medicaid Services (CMS)
Executive Office of the President (EOP)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
Labor, Dept of (DOL)
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 11

HR 3838
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 20…
HR 6400
Rx ACCESS Act
S 4106
Rx ACCESS Act
S 1542
DRUG Act
HR 2214
DRUG Act
HR 5378
Lower Costs, More Transparency Act
S 1339
Pharmacy Benefit Manager Reform Act
S 526
Pharmacy Benefit Manager Transparency Act of 2025
HR 7148
Consolidated Appropriations Act, 2026
HR 5582
Patients Deserve Price Tags Act
S 2355
Patients Deserve Price Tags Act

Lobbying activity 5

Medicare/Medicaid

Issues related to prior authorization; ACCESS (Advancing Chronic Care with Effective, Scalable Solutions) model

Health Issues

Issues relating to implementation of the No Surprises Act

Defense

H.R. 3838/S2296 Pharmacy issues related to the National Defense Authorization Act, FY2026 HR. 6400 / S. 4106 - Rx Access, Choice, Cost Equity, and Supply Stability (Rx ACCESS) Act

Pharmacy

S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; P.L. 119-75 Consolidated Appropriations Act, 2026 (H.R.7148) Issues related to the specialty drug market. H.R. 5582/S. 2355, Patients Deserve Price Tags Act

Labor Issues/Antitrust/Workplace

Issues related to competition in the health care marketplace.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.